anti-APRIL (human), mAb (blocking) (Mahya-1) (preservative free)
Method: BCMA(human):Fc (human) (rec.) is coated at 1µg/ml in PBS overnight at room temperature. After blocking and washing, APRIL (human) (H98) (multimeric) (rec.) is preincubated at 200ng/ml in the presence of anti-APRIL (human), mAb (blocking) (Mahya-1) or a control antibody (Prod. No. AG-20B-0063) starting at 5µg/ml with a twofold serial dilution. The binding of APRIL (human) (H98) (multimeric) (rec.) is detected by addition of a biotinylated anti-Flag antibody (1/4’000) for 1h at 37°C followed by streptavidin-HRP (1/4’000).
|Synonyms||A Proliferation Inducing Ligand; TNFSF13; CD256; TALL-2|
|Product Type||Monoclonal Antibody|
|Source/Host||Purified from concentrated hybridoma tissue culture supernatant.|
|Immunogen/Antigen||Recombinant human APRIL (aa 98-233).|
Recognizes human APRIL. Does not recognize mouse APRIL or mouse and human BAFF.
|Purity Detail||Protein A-affinity purified.|
|Endotoxin Content||<0.01EU/μg purified protein (LAL-test; Lonza)|
|Formulation||Liquid. In PBS.|
|Other Product Data||
Uniprot Link O75888: April (human)
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
After opening, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
Stable for at least 1 month after receipt when stored at +4°C.
Stable for at least 1 year after receipt when stored at -20°C.
|Product Specification Sheet|
The B cell-stimulating molecules, BAFF (B cell activating factor) and APRIL (a proliferation-inducing ligand), are critical factors in the maintenance of the B cell pool and humoral immunity. APRIL binds to transmembrane activator and CAML interactor (TACI), B cell maturation antigen (BCMA), and heparan sulfate proteoglycans (HSPG) within the extracellular matrix or on the surface of cells such as plasma cells. APRIL maintains B cell homeostasis by acting at a later stage, modulating the function and survival of antigen-experienced B cells. APRIL (as well as BAFF) stimulates class-switch recombination (CSR), hence contributes to shaping humoral effector mechanisms. With regards to humoral memory, APRIL is involved in the establishment and survival of the long-lived plasma cell (LLPC) pool in the bone marrow (BM). APRIL is expressed by a number of myeloid-derived cell types including BM granulocytes, megakaryocytes, eosinophils and osteoclasts and by dendritic cells following exposure to IFN-α, IFN-γ or CD40L. APRIL expression is induced during hematopoiesis in the bone marrow. APRIL expression is not limited to cells of myeloid origin, but can also be found in epithelial cells of the gut, tonsil, breast and skin. Finally, APRIL is expressed in tumor cell lines and human cancer cells of colon, thyroid and lymphoid origin. APRIL (a proliferation-inducing ligand) is implicated in several human autoimmune diseases with autoreactive B cell involvement, including systemic lupus erythematosus (SLE), Sjögren’s syndrome (SS), IgA nephropathy (IgAN) and rheumatoid arthritis (RA). APRIL might also function in enhancing proliferation of some tumor cells, especially B cell malignancies.